Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

This trial is studying a new formulation of a chemotherapy drug called irinotecan (delivered in lipid nanoparticles as LY01610) in patients with small cell lung cancer that came back 1–6 months after their first-line chemotherapy ended. **You may be eligible if:** - You are 18 or older with confirmed small cell lung cancer - Your cancer progressed 30 days to 6 months after completing at least 4 cycles of first-line platinum-based chemotherapy - You have at least one measurable tumor - Your life expectancy is at least 3 months and your physical functioning is good (ECOG score below 2) - Your blood counts, liver, and kidney function are within required ranges **You may NOT be eligible if:** - You have compound (mixed) small cell lung cancer - Your cancer has spread to the spinal cord or brain fluid (meningeal metastasis) - You have a prior treatment with irinotecan, topotecan, or other topoisomerase I inhibitors - You have active infections, significant heart disease, or active hepatitis B, C, or HIV - You are pregnant or breastfeeding - You received anticancer therapy within the past 4 weeks Talk to your doctor to see if this trial is right for you.